Advanced

Update on Clinical Trials in Dry Age-related Macular Degeneration.

Taskintuna, Ibrahim; Elsayed, M E A Abdalla and Schatz, Patrik LU (2016) In Middle East African Journal of Ophthalmology 23(1). p.13-26
Abstract
This review article summarizes the most recent clinical trials for dry age-related macular degeneration (AMD), the most common cause of vision loss in the elderly in developed countries. A literature search through websites https://www.pubmed.org and https://www.clinicaltrials.gov/, both accessed no later than November 04, 2015, was performed. We identified three Phase III clinical trials that were completed over the recent 5 years Age-Related Eye Disease Study 2 (AREDS2), implantable miniature telescope and tandospirone, and several other trials targeting a variety of mechanisms including, oxidative stress, complement inhibition, visual cycle inhibition, retinal and choroidal blood flow, stem cells, gene therapy, and visual... (More)
This review article summarizes the most recent clinical trials for dry age-related macular degeneration (AMD), the most common cause of vision loss in the elderly in developed countries. A literature search through websites https://www.pubmed.org and https://www.clinicaltrials.gov/, both accessed no later than November 04, 2015, was performed. We identified three Phase III clinical trials that were completed over the recent 5 years Age-Related Eye Disease Study 2 (AREDS2), implantable miniature telescope and tandospirone, and several other trials targeting a variety of mechanisms including, oxidative stress, complement inhibition, visual cycle inhibition, retinal and choroidal blood flow, stem cells, gene therapy, and visual rehabilitation. To date, none of the biologically oriented therapies have resulted in improved vision. Vision improvement was reported with an implantable mini telescope. Stem cells therapy holds a potential for vision improvement. The AREDS2 formulas did not add any further reduced risk of progression to advanced AMD, compared to the original AREDS formula. Several recently discovered pathogenetic mechanisms in dry AMD have enabled development of new treatment strategies, and several of these have been tested in recent clinical trials and are currently being tested in ongoing trials. The rapid development and understanding of pathogenesis holds promise for the future. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Middle East African Journal of Ophthalmology
volume
23
issue
1
pages
13 - 26
publisher
Medknow Publications and Media Pvt. Ltd
external identifiers
  • pmid:26957835
  • scopus:84954515472
  • wos:000373949300003
ISSN
0975-1599
DOI
10.4103/0974-9233.173134
language
English
LU publication?
yes
id
81455f1c-b9ce-4631-a63e-20dea761b0eb (old id 8852960)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/26957835?dopt=Abstract
date added to LUP
2016-03-15 13:37:48
date last changed
2017-01-01 07:49:13
@article{81455f1c-b9ce-4631-a63e-20dea761b0eb,
  abstract     = {This review article summarizes the most recent clinical trials for dry age-related macular degeneration (AMD), the most common cause of vision loss in the elderly in developed countries. A literature search through websites https://www.pubmed.org and https://www.clinicaltrials.gov/, both accessed no later than November 04, 2015, was performed. We identified three Phase III clinical trials that were completed over the recent 5 years Age-Related Eye Disease Study 2 (AREDS2), implantable miniature telescope and tandospirone, and several other trials targeting a variety of mechanisms including, oxidative stress, complement inhibition, visual cycle inhibition, retinal and choroidal blood flow, stem cells, gene therapy, and visual rehabilitation. To date, none of the biologically oriented therapies have resulted in improved vision. Vision improvement was reported with an implantable mini telescope. Stem cells therapy holds a potential for vision improvement. The AREDS2 formulas did not add any further reduced risk of progression to advanced AMD, compared to the original AREDS formula. Several recently discovered pathogenetic mechanisms in dry AMD have enabled development of new treatment strategies, and several of these have been tested in recent clinical trials and are currently being tested in ongoing trials. The rapid development and understanding of pathogenesis holds promise for the future.},
  author       = {Taskintuna, Ibrahim and Elsayed, M E A Abdalla and Schatz, Patrik},
  issn         = {0975-1599},
  language     = {eng},
  number       = {1},
  pages        = {13--26},
  publisher    = {Medknow Publications and Media Pvt. Ltd},
  series       = {Middle East African Journal of Ophthalmology},
  title        = {Update on Clinical Trials in Dry Age-related Macular Degeneration.},
  url          = {http://dx.doi.org/10.4103/0974-9233.173134},
  volume       = {23},
  year         = {2016},
}